WILMINGTON PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 368 GBX | +4.55% |
|
+3.08% | +10.84% |
| Apr. 26 | Wilmington sells French healthcare business APM for EUR26 million | AN |
| Apr. 26 | Wilmington Sells French Healthcare Unit for EUR26 million | MT |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
Strengths
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Consumer Publishing
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +10.84% | 409M | C+ | ||
| +9.50% | 6.43B | B | ||
| +38.74% | 5.07B | - | - | |
| +14.98% | 3.56B | D- | ||
| +21.44% | 3.06B | C- | ||
| +8.71% | 3B | B+ | ||
| -1.11% | 2.42B | - | ||
| +7.85% | 1.71B | - | ||
| +17.55% | 1.64B | C+ | ||
| +0.54% | 1.25B | - | - |
Investor Rating
Trading Rating
-
ESG Refinitiv
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
-
Finances
Valuation
P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
-
4 months EPS revision
-
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- WIL Stock
- Ratings Wilmington plc
